Vertiva®, Next-generation On-Body Delivery System

Paris once again welcomes Europe’s leading trade show in pharmaceutical packaging and drug delivery innovation. Join our content team as Pharmapack 2024 opens its doors to leading experts and innovators in pharmaceutical packaging and drug delivery. 

Assembly Equipment combining transport platforms and process modules: an offer of manual, semi-automatic or fully automatic assembly lines customized to your device program.

This January Pharmapack Europe is once again bringing the epicentre of all things pharmaceutical packaging to Paris, France. This year, to enhance our sustainability offering at the event, we are partnering with Stevanato Group. In the following interview Stevanato Group explains why sustainability is so important to them. 

A flexible mid-high speed pen injector line assembling different formats and integrating extensive in-process controls.

The Aidaptus® disposable auto-injector platform, designed by Owen Mumford, will be jointly offered to global biopharma companies to support their drug development programs with engineering and manufacturing support provided by Stevanato Group.

Alina® is a variable-dose pen injector developed by Stevanato Group based on Axis-D intellectual property and technology exclusively licensed from pen injector device expert Haselmeier, for the treatment of diabetes, obesity, and other therapeutic areas.

Leveraging the established EZ-fill® market leading technology, process, and product optimisation to improve quality, reduce total cost of ownership, and shorten lead times.

How RTU vials and cartridges can be a suitable, time-efficient and cost-effective answer to meet new regulation requirements.

The Company offers the platform as a readily customizable pre-filled and pre-loaded on-body solution for drug delivery. Device development is making significant progress, with samples expected to be available in 2023.

Learn more from this White Paper providing insights on tests and solutions performed on primary packaging to overcome mRNA challenges.

Tremendous growth opportunities exist for auto-injectors as their value is increasingly being recognised across several therapy areas, experts have told a recent CPHI webinar, sponsored by Stevanato Group.

Artificial Intelligence (AI) has triggered a fundamental shift within the innovation paradigm for the pharmaceutical industry and has been implemented in almost every aspect of the value chain, from drug discovery and development to manufacturing. One application of AI which offers particular value is the realm of visual inspections, which present a challenging step in the packaging process. This is particularly true for products with complex characteristics where manual inspections can sometimes fall short, leading to errors and inconsistencies. AI learning models can optimise the packaging process by detecting minute errors, resulting in fewer rejects, less intervention and a more efficient process overall. This webinar will tackle some of the key drivers and benefits to implementing AI for pharma visual inspections to enhance performance, improve accuracy, efficiency and overall quality.

Watch this recent webinar exploring the challenges of distributing COVID-19 vaccines to a global population and the role the packaging sector is playing to ensure safe and speedy distribution of shots

Advances in auto-injector design now provide the option to use both 1ml and 2.25mL syringes plus employ technology to adapt to varying fill volumes and viscosities all whilst maintaining the same device form. This provides a solution for the formulation changes that take place during drug development, clinical trials, and life cycle management. When looking at the performance of any parenteral injection device, the drug containment systems play a crucial role. Auto-injector performance and functionality is strictly linked to key dimensional tolerances of glass syringes. We will illustrate the importance of syringe design to ensure these requirements and how monitoring dimensional parameters at an early stage of the development is key to ensure the intended use and ultimately work to preserve patients’ safety. Benefits of tight collaboration between device designer and manufacturer will also be discussed.

Patients suffering from chronic and acute pain disorders will benefit from a convenient, discreet, and easy-to-use device delivering a novel alternative to opioid-based pain management.

Due to begin operations in late September, the US TEC will bring value-added laboratory services to the heart of the biotech community.

In this article, Stevanato Group discusses the challenges faced in administering highly viscous biologics to patients via subcutaneous injection and how its special thin-wall needles can tackle them.

The Vision Robot Unit will provide biopharma companies with a fully automatized, highly accurate and flexible inspection system equipped with artificial intelligence for a variety of drug products, for increased operational efficiency.

Discover how Stevanato Group helps pharma companies identify relevant testing to de-risk the product development lifecycle and quickly uncover the root causes of product failures.

In a compressed timeframe, producing large quantities of pharmaceutical glass containers to deliver the coronavirus vaccine around the world is a critical factor for a successful global response. Type 1 glass is a proven and widely available solution for pharma glass containers that preserves the stability of vaccines. Players in the pharmaceutical supply chain are committed to supporting pharmaceutical companies and governments in the fight against the pandemic.